Purpose: This study aimed to analyze the characteristics and outcomes of patients with an aortoduodenal fistula (ADF) who underwent surgical treatment at a single institution. Materials and Methods: The data of patients diagnosed with ADF at the Yonsei University Gangnam Severance Hospital, South Korea, between 2019 and 2022 were included. Primary repair and segmental resection of the duodenum with duodeno-jejunostomy were the two main methods used to repair ADF. Results: Among the 15 patients analyzed, most were male, and the median age was 68 years. Based on the cause of ADF, five patients had primary ADF, whereas the remaining had secondary ADF. The average duration from fistula diagnosis to surgery was 23.5 days (2.8 days in primary ADF cases and 33.8 days in secondary ADF cases). Primary repair of the ADF was performed for eight patients, and segmental resection of the duodenum with duodeno-jejunostomy was performed for the remaining patients.Omentopexy was performed for all patients. The median duration of hospital stay was 32.7 days. Three patients died after surgery;however, all 11 patients operated on by the single experienced surgeon survived until the last follow-up. Conclusion To the best of our knowledge, this study is the first original article on ADF. Our findings suggest that ADF repairs performed by experienced surgeons would provide favorable results. Although primary repair is the first treatment choice, duodenojejunostomy is recommended when it is not feasible. By choosing the appropriate procedure depending on the case, favorable outcomes without any fatalities can be achieved.

Background: Skipping breakfast is associated with an increased risk of chronic inflammatory diseases. This study aimed to examine the association between breakfast-eating habits and inflammation, using high-sensitivity C-reactive protein (hs-CRP) as a marker. Methods: A total of 4,000 Korean adult males with no history of myocardial infarction, angina, stroke, diabetes, rheumatoid arthritis, cancer, or current smoking were included. Data from the 2016–2018 Korea National Health and Nutrition Examination Survey were used for analysis. The frequency of breakfast consumption was assessed through a questionnaire item in the dietary survey section asking participants about their weekly breakfast consumption routines over the past year. Participants were categorized into two groups, namely “0–2 breakfasts per week” and “3–7 breakfasts per week”; hs-CRP concentrations were measured through blood tests. Results: Comparing between the “infrequent breakfast consumption (0–2 breakfasts per week)” and “frequent breakfast consumption (3–7 breakfasts per week)” groups, the mean hs-CRP was found to be significantly higher in the “infrequent breakfast consumption” group, even after adjusting for age, body mass index, physical activity, alcohol consumption, systolic blood pressure, blood pressure medication, fasting blood glucose, and triglycerides (mean hs-CRP: frequent breakfast consumption, 1.36±0.09 mg/L; infrequent breakfast consumption, 1.17±0.05 mg/L; P-value=0.036). Conclusion Less frequent breakfast consumption was associated with elevated hs-CRP levels. Further large-scale studies incorporating adjusted measures of daily eating patterns as well as food quality and quantity are required for a deeper understanding of the role of breakfast in the primary prevention of chronic inflammatory diseases.

Background: The novel sodium-glucose cotransporter-2 (SGLT2) inhibitor enavogliflozin effectively lowers glycosylated hemoglobin levels and body weights without the increased risk of serious adverse events; however, the long-term clinical benefits of enavogliflozin in terms of cardiovascular and renal outcomes have not been investigated. Methods: This study is an investigator-initiated, multicenter, randomized, pragmatic, open-label, active-controlled, non-inferiority trial. Eligible participants are adults (aged ≥19 years) with type 2 diabetes mellitus (T2DM) who have a history of, or are at risk of, cardiovascular disease. A total of 2,862 participants will be randomly assigned to receive either enavogliflozin or other SGLT2 inhibitors with proven cardiorenal benefits, such as dapagliflozin or empagliflozin. The primary endpoint is the time to the first occurrence of a composite of major adverse cardiovascular or renal events (Clinical Research Information Service registration number: KCT0009243). Conclusion This trial will determine whether enavogliflozin is non-inferior to dapagliflozin or empagliflozin in terms of cardiorenal outcomes in patients with T2DM and cardiovascular risk factors. This study will elucidate the role of enavogliflozin in preventing vascular complications in patients with T2DM.

Purpose: This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea. Materials and Methods: Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response. Results: Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression. Conclusion This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.

Purpose: This study aimed to analyze the characteristics and outcomes of patients with an aortoduodenal fistula (ADF) who underwent surgical treatment at a single institution. Materials and Methods: The data of patients diagnosed with ADF at the Yonsei University Gangnam Severance Hospital, South Korea, between 2019 and 2022 were included. Primary repair and segmental resection of the duodenum with duodeno-jejunostomy were the two main methods used to repair ADF. Results: Among the 15 patients analyzed, most were male, and the median age was 68 years. Based on the cause of ADF, five patients had primary ADF, whereas the remaining had secondary ADF. The average duration from fistula diagnosis to surgery was 23.5 days (2.8 days in primary ADF cases and 33.8 days in secondary ADF cases). Primary repair of the ADF was performed for eight patients, and segmental resection of the duodenum with duodeno-jejunostomy was performed for the remaining patients.Omentopexy was performed for all patients. The median duration of hospital stay was 32.7 days. Three patients died after surgery;however, all 11 patients operated on by the single experienced surgeon survived until the last follow-up. Conclusion To the best of our knowledge, this study is the first original article on ADF. Our findings suggest that ADF repairs performed by experienced surgeons would provide favorable results. Although primary repair is the first treatment choice, duodenojejunostomy is recommended when it is not feasible. By choosing the appropriate procedure depending on the case, favorable outcomes without any fatalities can be achieved.

Purpose: This study aimed to analyze the characteristics and outcomes of patients with an aortoduodenal fistula (ADF) who underwent surgical treatment at a single institution. Materials and Methods: The data of patients diagnosed with ADF at the Yonsei University Gangnam Severance Hospital, South Korea, between 2019 and 2022 were included. Primary repair and segmental resection of the duodenum with duodeno-jejunostomy were the two main methods used to repair ADF. Results: Among the 15 patients analyzed, most were male, and the median age was 68 years. Based on the cause of ADF, five patients had primary ADF, whereas the remaining had secondary ADF. The average duration from fistula diagnosis to surgery was 23.5 days (2.8 days in primary ADF cases and 33.8 days in secondary ADF cases). Primary repair of the ADF was performed for eight patients, and segmental resection of the duodenum with duodeno-jejunostomy was performed for the remaining patients.Omentopexy was performed for all patients. The median duration of hospital stay was 32.7 days. Three patients died after surgery;however, all 11 patients operated on by the single experienced surgeon survived until the last follow-up. Conclusion To the best of our knowledge, this study is the first original article on ADF. Our findings suggest that ADF repairs performed by experienced surgeons would provide favorable results. Although primary repair is the first treatment choice, duodenojejunostomy is recommended when it is not feasible. By choosing the appropriate procedure depending on the case, favorable outcomes without any fatalities can be achieved.

Background: Skipping breakfast is associated with an increased risk of chronic inflammatory diseases. This study aimed to examine the association between breakfast-eating habits and inflammation, using high-sensitivity C-reactive protein (hs-CRP) as a marker. Methods: A total of 4,000 Korean adult males with no history of myocardial infarction, angina, stroke, diabetes, rheumatoid arthritis, cancer, or current smoking were included. Data from the 2016–2018 Korea National Health and Nutrition Examination Survey were used for analysis. The frequency of breakfast consumption was assessed through a questionnaire item in the dietary survey section asking participants about their weekly breakfast consumption routines over the past year. Participants were categorized into two groups, namely “0–2 breakfasts per week” and “3–7 breakfasts per week”; hs-CRP concentrations were measured through blood tests. Results: Comparing between the “infrequent breakfast consumption (0–2 breakfasts per week)” and “frequent breakfast consumption (3–7 breakfasts per week)” groups, the mean hs-CRP was found to be significantly higher in the “infrequent breakfast consumption” group, even after adjusting for age, body mass index, physical activity, alcohol consumption, systolic blood pressure, blood pressure medication, fasting blood glucose, and triglycerides (mean hs-CRP: frequent breakfast consumption, 1.36±0.09 mg/L; infrequent breakfast consumption, 1.17±0.05 mg/L; P-value=0.036). Conclusion Less frequent breakfast consumption was associated with elevated hs-CRP levels. Further large-scale studies incorporating adjusted measures of daily eating patterns as well as food quality and quantity are required for a deeper understanding of the role of breakfast in the primary prevention of chronic inflammatory diseases.